Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825233 | Clinical Therapeutics | 2014 | 15 Pages |
Abstract
GIC-1001 was well tolerated, and its safety profile was similar to that of placebo. Pharmacokinetics of GIC-1001 and its metabolites were mainly linear and proportional over the studied dose ranges. Steady state was generally considered to be reached after 3 days. Food consumption affected the pharmacokinetic profile of the analytes differently. (ClinicalTrials.gov identifier: NCT01738425.)
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jean-Michel BSc, Marianne PhD, Mirela MD, MSc, Julie BSc, Marc BPharm, PhD, Patrick BPharm, PhD, Ariles BSc, Maxime PhD, MBA,